Medline ® Abstract for Reference 142
of 'Chemotherapy hepatotoxicity and dose modification in patients with liver disease'
Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.
van Hazel GA, Scott M, Rubin J, Moertel CG, Eagan RT, O'Connell MJ, Kovach JS
Cancer Treat Rep. 1983;67(9):805.
We have characterized plasma pharmacokinetics in 30 patients receiving mitomycin C (mitomycin) in doses ranging from 6 to 20 mg/m2 by iv bolus injection, either alone or in combination with other chemotherapeutic drugs. Plasma elimination of the drug was described by a two-compartment model in all but three cases, giving mean values for alpha-half-life of 8.2 mins, beta-half-life of 51.8 mins, and total body clearance of 332.9 ml/min/m2. The mean urinary excretion was 8.1% of the total dose administered. We did not detect alterations in pharmacologic parameters related to liver dysfunction, dose of mitomycin, and concomitant administration of other cytotoxic drugs.